Trial Profile
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety and Immunogenicity of Neovacs' TNFalpha-Kinoid in Adult Subjects With Crohn's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Tumour necrosis factor-alpha kinoid (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Neovacs
- 17 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 01 Aug 2013 Planned end date changed from 1 Jun 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 20 Nov 2012 Final results have been reported in a Neovacs media release.